share_log

Beyond Air Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

Beyond Air Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

Beyond Air Schedules 2024 財年末財務業績電話會議和網絡直播
GlobeNewswire ·  05/24 04:09

Conference call scheduled for Monday, June 24th at 4:30 pm ET

電話會議定於美國東部時間6月24日星期一下午 4:30 舉行

GARDEN CITY, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. ("Beyond Cancer")), today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2024 on Monday, June 24, 2024. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

紐約州加登城,2024年5月23日(GLOBE NEWSWIRE)——Beyond Air, Inc.(納斯達克股票代碼:XAIR)(“Beyond Air” 或 “公司”)是一家商業階段的醫療器械和生物製藥公司,專注於利用內源和外源性一氧化氮(NO)的力量改善呼吸系統疾病、神經系統疾病和實體瘤患者的生活(通過其子公司Beyond)Cancer, Ltd.(“Beyond Cancer”)今天宣佈,將於6月24日星期一公佈截至2024年3月31日的第四財季和全年財務業績,2024。該公司的管理團隊計劃於美國東部時間當天下午 4:30 舉行電話會議和網絡直播。

Conference Call & Webcast
Monday, June 24th @ 4:30 PM ET
Domestic:
1-877-407-0784
International: 1-201-689-8560
Conference ID: 13746892
Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company's website (click here) or directly (click here). An online replay will be available on the Company's website or via the direct link an hour after the call.
電話會議和網絡直播
6月24日星期一第四 @ 美國東部時間下午 4:30
國內:
1-877-407-0784
國際: 1-201-689-8560
會議編號: 13746892
網絡直播: 可以通過訪問公司網站的 “活動” 部分(點擊此處)或直接(點擊此處)觀看電話會議的網絡直播。電話會議結束一小時後,將在公司網站上或通過直接鏈接進行在線重播。

About Beyond Air, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit .

Beyond Air簡介, Inc.
Beyond Air是一家商業階段的醫療設備和生物製藥公司,致力於利用內源性和外源性一氧化氮(NO)的力量來改善呼吸系統疾病、神經系統疾病和實體瘤患者的生活。該公司的第一個系統LungFit已獲得美國食品藥品管理局的批准 PH,用於治療患有缺氧呼吸衰竭的足月和近期新生兒。Beyond Air目前正在臨床試驗中推進其其他革命性的LungFit系統,用於治療嚴重的肺部感染,例如病毒性社區獲得性肺炎(包括 COVID-19)和非結核分枝桿菌(NTM)等。此外,該公司還與耶路撒冷希伯來大學合作,推進了一項專門治療自閉症譜系障礙(ASD)和其他神經系統疾病的臨床前項目。此外,Beyond Air的子公司Beyond Cancer, Ltd. 正在研究採用專有輸送系統的超高濃度氮氣,以在臨床前環境中靶向某些實體瘤。欲了解更多信息,請訪問。

Forward Looking Statements
This press release contains "forward-looking statements" concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words "appears," "expects," "plans," "anticipates," "believes" "expects," "intends," "looks," "projects," "goal," "assumes," "targets" and similar expressions and/or the use of future tense or conditional constructions (such as "will," "may," "could," "should" and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the "Risk Factors" section of Beyond Air's most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air's website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.

前瞻性陳述
本新聞稿包含有關吸入一氧化氮和超高濃度一氧化氮候選產品的潛在安全性和有效性及其在多種適應症中的治療潛力的 “前瞻性陳述”;以及吸入一氧化氮和超高濃度一氧化氮候選產品對患者的潛在影響和預期益處。前瞻性陳述包括有關產品供應、業務、經營業績、戰略或前景的預期、信念或意向的陳述。你可以通過 “出現”、“期望”、“計劃”、“預期”、“相信”、“打算”、“外觀”、“項目”、“目標”、“假設”、“目標” 和類似表述和/或使用未來時態或條件結構(例如 “將”、“可能”、“應該” 等)來識別此類前瞻性陳述這些陳述並不完全涉及歷史或當前問題。相反,前瞻性陳述涉及截至發表之日的預期或預期事件、活動、趨勢或結果。由於前瞻性陳述涉及尚未發生的事項,因此這些陳述本質上受風險和不確定性的影響,可能導致實際業績與前瞻性陳述所表達或暗示的任何未來業績存在重大差異。這些前瞻性陳述只是預測,反映了截至發表之日對未來事件和財務業績的看法。許多因素可能導致實際活動或結果與前瞻性陳述中預期的活動和結果存在重大差異,包括與完成發行相關的活動或結果、與籌集額外資金能力相關的風險;未來臨床前研究和臨床試驗的時間和結果;監管機構,包括美國食品藥品管理局和類似的非美國監管機構,可能不批准或推遲批准我們的候選產品;發現和開發新藥的方法未經證實,可能永遠不會帶來有效或適銷對路的產品;爲我們的候選產品提供資金的能力和進一步臨床前研究和臨床試驗的結果;獲得、維護和保護產品使用的知識產權;獲得監管部門對產品的批准;來自使用類似技術和其他人爲類似用途開發產品的競爭;對合作者的依賴;以及其他風險,這些風險可能在 Beyond Air 的 “風險因素” 部分中進行識別和描述最近的一年一度的關於10-K表格及其向美國證券交易委員會提交的其他文件的報告,所有這些文件均可在Beyond Air的網站上查閱。除非適用法律要求,否則Beyond Air和Beyond Cancer沒有義務更新這些前瞻性陳述,也沒有更新或修改這些前瞻性陳述的政策。

CONTACTS:

聯繫人:

Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577

科裏·戴維斯博士
LifeSci 顧問有限公司
Cdavis@lifesciadvisors.com
(212) 915-2577


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論